ReviewNeuro-oncology practice2025
Cancer-related movement disorders: A scoping review and diagnostic approach.
Review in Neuro-oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Spectrum of Movement Disorders in Hematological Malignancies: A Comprehensive Systematic Review of Clinical Phenotypes, Mechanisms, and Outcomes.Tremor and other hyperkinetic movements (New York, N.Y.) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-related movement disorders (CRMDs) comprise a diverse group of neurological complications of cancer. They result from varied etiologies and can be associated with compromised quality of life and poor prognosis. CRMDs can be divided into two broad categories: movement disorders resulting from cancer-related processes, such as direct tumor infiltration and paraneoplastic disease, and those that are a consequence of cancer-directed treatments, including classic therapies, such as chemotherapy and radiation therapy, novel treatments (eg immunotherapies and CAR T-Cell therapies), and various supportive treatments. A clear understanding of the breadth of CRMDs is vital, as effective management relies upon accurately identifying their underlying etiology. In this scoping review, we provide a comprehensive categorization of CRMDs based on their underlying etiology and phenomenology. Additionally, we propose a structured framework to guide the diagnostic evaluation and management of CRMDs, with the goal of facilitating timely diagnosis and, ultimately, improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.